Table 2.
Comparison of non-failure and failure with tofacitinib
| Characteristics at enrollment | Non-failure n = 16 |
Failure n = 6 |
|---|---|---|
| Age (years) | 44.19 (16.33) | 50.00 (16.58) |
| Males/females, n (%) | 8/8 (50.0/50.0) | 5/1 (83.3/16.7) |
| Disease duration (years) | 8.18 (7.37) | 4.50 (6.63) |
| Disease extent | ||
| Extensive colitis | 8 (50.0) | 6 (100.0) |
| Left-sided colitis | 7 (43.8) | 0 (0.0) |
| Proctitis | 1 (6.2) | 0 (0.0) |
| CAI (Rachmilewitz index) | 4.75 (1.77) | 5.00 ± 2.19 |
| CRP (mg/dL) | 0.53 (1.28) | 0.30 (0.36) |
| Alb (g/dL) | 4.11 (0.50) | 3.83 (0.43) |
| Hb (g/dL) | 12.82 (1.76) | 13.02 (2.62) |
| MES | ||
| MES 0 | 0 (0.0) | 1 (16.7) |
| MES 1 | 6 (37.5) | 0 (0.0) |
| MES 2 | 9 (56.2) | 3 (50.0) |
| MES 3 | 1 (6.2) | 2 (33.3) |
| UCEIS | 3.62 (1.20) | 5.33 (1.03) |
| Other medications | ||
| Oral 5-ASA | 10 (62.5) | 3 (50.0) |
| Suppository steroids | 3 (18.8) | 0 (0.0) |
| Systemic steroids | 2 (12.5) | 1 (16.7) |
| History of biologics use | 7 (43.8) | 3 (50.0) |
Data are presented as mean ± standard deviation or n (%)
CAI clinical activity index, CRP C-reactive protein, Alb albumin, Hb hemoglobin, MES Mayo endoscopic subscore, UCEIS ulcerative colitis endoscopic index of severity, 5-ASA 5-aminosalicylic acid